In vivo, the loss of NLRP3 inflammasome or caspase-1 activity has been found to inhibit the priming and activation of CTLs, thereby significantly blocking the cytotoxic effects of CTLs against tumour cells in mouse models [50,59]. The gene discussed is CASP1; the disease is neoplasm.